You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR MEXATE-AQ


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mexate-aq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002798 ↗ Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 3 1996-08-01 Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed Children's Cancer Group Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mexate-aq

Condition Name

Condition Name for Mexate-aq
Intervention Trials
Acute Lymphoblastic Leukemia 27
Untreated Adult Acute Lymphoblastic Leukemia 17
Recurrent Adult Acute Myeloid Leukemia 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mexate-aq
Intervention Trials
Leukemia 85
Precursor Cell Lymphoblastic Leukemia-Lymphoma 73
Leukemia, Lymphoid 73
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mexate-aq

Trials by Country

Trials by Country for Mexate-aq
Location Trials
Canada 171
Australia 73
New Zealand 25
Puerto Rico 18
Japan 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mexate-aq
Location Trials
Texas 64
Washington 53
California 53
Ohio 52
Pennsylvania 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mexate-aq

Clinical Trial Phase

Clinical Trial Phase for Mexate-aq
Clinical Trial Phase Trials
Phase 4 1
Phase 3 32
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mexate-aq
Clinical Trial Phase Trials
Completed 52
Active, not recruiting 30
Recruiting 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mexate-aq

Sponsor Name

Sponsor Name for Mexate-aq
Sponsor Trials
National Cancer Institute (NCI) 110
Children's Oncology Group 25
M.D. Anderson Cancer Center 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mexate-aq
Sponsor Trials
NIH 119
Other 112
Industry 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.